Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) reported an attributable net profit of 1.72 billion yuan for the first half, up 1.15% from 1.70 billion yuan a year earlier.
Earnings per share stood at 0.65 yuan, inching up from 0.64 yuan in the year-ago period, according to a Tuesday filing with the Hong Kong bourse.
Revenue increased 4.75% year over year to 20.4 billion yuan from 19.4 billion yuan.